The use of atypical neuroleptics in psychotic disorders has steadily increased since 1989, and atypical neuroleptics have become the first line of treatment, for psychotic disorders. Since the marketing of clozapine in 1989 in the USA, several other atypical neuroleptics have become available to clinicians there, and this has extended and diversified the prescriptions of atypical neuroleptics. However, no newer atypical neuroleptic has yet shown greater efficacy than clozapine. In addition, many patients have improved only partially with these newer atypical neuroleptics. Clinicians often face difficult choices when patients do not respond or partially respond to these newer atypicals. Several strategic possibilities are then available to clinicians: (i) increasing the dosage of the antipsychotic; (ii) switching to another neuroleptic; (iii) augmenting treatment with a mood stabilizer; and (iv) using polypharmacy (meaning adding a second antipsychotic medication). Before adding any other medication, or changing to another neuroleptic, a fundamental question should be answered: has the current neuroleptic been optimally used? This question can be divided into two different, questions: has the length of the medication trial been long enough, and has the patient received an optimal dosage?

In this presentation, we will focus on the second question: what is the optimal dosage for the atypical neuroleptics? We will limit the neuroleptics to the atypical agents currently available in the USA (clozapine, risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole), and thus we will not discuss dosing issues regarding other atypicals such as sertindole or amisulpride.

Lessons from typical neuroleptics
=================================

The issue of optimal dosage with typical neuroleptics has been the focus of frequent, debates. For example, in the seventies, very high doses of haloperidol were routinely used. However, it became clear that high doses can lead to more side effects and particularly to more extrapyramidal side effects (EPS). In the nineties, an opposite trend arose: it was considered that, much lower doses than 30 mg/day were sufficient, to obtain optimal efficacy. This was supported by positron emission tomography (PET) studies that, showed that small daily doses such as 5 mg were sufficient, to obtain more then 60% blockade of the dopamine D~2~ receptors in the basal ganglia. Consequently, the average daily dosage of typical neuroleptics has decreased in clinical settings and in clinical research trials (eg, when haloperidol is used as a comparative treatment arm). One remaining issue is to identify patients who may need higher doses. Although it is commonly accepted that fast mctabolizcrs need higher doses, there is very little evidence to support, the use of high doses in other circumstances. Clinicians tend to increase neuroleptic doses, and sometimes up to high doses, for breakthrough symptoms and for a partial response. One study^[@ref1]^ found that patients who receive high doses of typical neuroleptics tend to show a more severe course of illness and more persistent symptoms, and some had a history of violence or regressed behavior.

What doses do clinicians prescribe?
===================================

In the USA, clinical use of atypicals began in 1989 with clozapine. At that, time, it was commonly accepted that, the average daily dose should be around 500 to 600 mg. It is of note that, in the last 5 years, publications report, that, in Europe the average daily dose of clozapine has been much lower (around or below 300 mg), and at the same time, the average daily dose of clozapine has decreased in the USA, as seen in psychiatric hospitals operated by the State of New York *(Table I).^[@ref2]^* State hospitals in the USA are dedicated to the treatment of people with mental illness who have minimal or no insurance, and who need longer hospital stays. For these reasons, patients in state hospitals are mostly those with schizophrenia or schizoaffective disorder, and who also have frequent relapses, or who do not show a good and fast response to *therapy,* and are thus the most challenging patient population to treat. The average daily doses of clozapine and risperidone have decreased in the last 5 years, while the average daily dose of olanzapine has increased, almost reaching the maximal recommended dose. This current practice does not seem specific to New York State. Stahl^[@ref3]^ reported that, in California, the average daily dose in 2002 was 4.0 mg for risperidone, 20.5 mg for olanzapine, and 316 mg for quetiapine (for patients aged 1 8 to 44). Although the patient populations were not quite comparable between these two reports, it appears that clinicians use a lower daily dose of risperidone than before, whereas they use higher doses of olanzapine.

###### Recommended daily doses of neuroleptics, and neuroleptic doses used in New York State Hospitals. FDA, Food and Drug Administration. Data taken from reference 2.

  **Antipsychotic**   **Daily doses recommended by the FDA (mg)**   **New York State Hospitals Mean daily dose used (mg)**   
  ------------------- --------------------------------------------- -------------------------------------------------------- ---------------
  Clozapine           300-450; maximum: 900                         586.3 (N=845)                                            494.7 (N=851)
  Risperidone         4-8; maximum:16                               7.1 (N=1320)                                             4.9 (N=1552)
  Olanzapine          10-15; maximum: 20                            15.6 (N=1057)                                            18.9 (N=1662)
  Quetiapine          300-500; maximum: 800                         Not availabe                                             518.4 (N=782)
  Ziprasidone         40-160; maximum: 200                          Not availabe                                             132.4 (N=129)

Evidence for an optimal dose of atypical neuroleptics
=====================================================

For all atypicals, studies have shown that very low doses are no better than placebo, so the question of finding the optimal dose can be summarized as: is more medication more efficacious? There are two ways to measure the quantity of medication each patient receives: daily dose and plasma level. Usually, when plasma levels are studied, the question that researchers try to answer is: is there a drug plasma level that should be reached in order to obtain an optimal response? To answer this, a specific statistical tool is used: the receiver operating characteristics (ROC) curves. These curves are obtained by ranking each patient from the highest plasma level to the lowest, plasma level. Rach case is then plotted on a graph: the *y* axis represents the cumulative percentage of responders (which is also the sensitivity of the cutoff point), while the *x* axis represent, the cumulative percentage of nonresponders (which will give the specificity of the cutoff point, by subtracting this number from 1). From the curve, a cutoff point is determined, and a chi-square analysis is undertaken to determine whether the percentage of responders among patients with a plasma level above the cutoff point, is significantly different from the rate of responders with a plasma level under the cutoff point. We will now review the evidence for high dosing for each atypical neuroleptic.

Clozapine
---------

Several studies^[@ref4]-[@ref10]^ have tried to determine a threshold for the clozapine plasma level, above which a response could be predicted *(Table IT).* Comparison between these studies is made difficult as they vary greatly in their methodologies. .For example, some used a fixed dose, while others did not (which leads to a lower percentage of responders in the high doses, and thus makes it difficult to identify a threshold). However, it can be concluded that 350 ng/mL can be considered as a plasma threshold for optimal clozapine therapy. Moreover, several remarks need to be made:

-   350 ng/mL is not a "magical" number. A good percentage of patients do improve even with plasma levels lower than 350 ng/mL. This means that for patients who do not respond or partially respond to clozapine, and who have a plasma level below 350 ng/mL, efforts should be made to obtain a clozapine plasma level above 350 ng/mL, before establishing that these patients are clozapine nonresponders.

-   The dosage of clozapine plus norclozapine does not add precision in the determination of a threshold compared with clozapine plasma level alone.

-   Clozapine plasma levels vary greatly between individuals. This is quite important, and some patients with a daily dose of 900 mg may not achieve a plasma level of 350 ng/mL, while some patients even with a low daily dose may show a plasma level a good deal higher than 350 ng/mL.

-   A higher plasma level is associated with a higher risk of seizures.

-   The dosing schedule should be taken into consideration. As clozapine has an average half-life of 1 2 h, a daily dosing schedule of 400 mg at night, will lead to a higher plasma level than a dosing schedule of 200 mg twice a day, even if levels are drawn 12 h after the last dose in both cases. This may explain some discrepancies between the results of the studies examining plasma levels.

-   In all these studies, blood was drawn 12 h after the last clozapine dose. Clinicians should make sure that plasma levels are checked exactly 12 h after the last clozapine dose. Again, as the half-life of clozapine is around 12 h, a plasma level of 350 ng/mL at 12 h, will drop to 310 ng/mL at 13 h. Although this might, not be a difficult problem to resolve with inpatients, it can be quite a challenge with outpatients.

###### Studies of clozapine plasma levels and response rates. BPRS, Brief Psychiatric Rating Scale; NA, not available; NS, not significant; PANSS, Positive and Negative Syndrome Scale.

  **Reference**                       **N**   **Duration (weeks)**   **Fixed dosage (mg/day)**   **Mean dosage (mg/day)**                  **Criteria for improvement**   **Cutoff plasma level (ng/mL)**   **Response rate**                   **Sensitivity/specificity**   **Remarks**
  ----------------------------------- ------- ---------------------- --------------------------- ----------------------------------------- ------------------------------ --------------------------------- ----------------------------------- ----------------------------- -----------------------------
  Perry et al,^[@ref4]^ 1991          29      4                      400                         384±42                                    BPRS≥20%                       350                               64% vs 22% P=0.03                   64%/78%                       Dose given at bedtime
  Hasegawa et al,^[@ref5]^ 1993       59      26                     No                          444±270                                   BPRS≥20%                       370                               73% vs 38% P=0.01                   53%/73%                       Level at D29 to D2288
  Potkin et al,^[@ref6]^ 1994         58      12                     400 for 6 weeks             Then 400 or 800                           BPRS≥20%                       420                               60% vs 8% at W4 73% vs 23% at W12   74% NA                        Frequency?
  Kronig et al,^[@ref7]^ 1995         45      6                      500 for 3 weeks             623±203                                   BPRS≥20%                       350                               55% vs 20 % P\<0.04                 80%/54%                       Dose given BID
  VanbderZwaag et al,^[@ref8]^ 1996   56      12                     NA                          Plasma; 50-150, 200-300, 350-450 309+63   BPRS≥20% ≥33%                  \>200-300                         60% vs 39% NS 42% vs 6% P=0.04                                    BID or TID
  Spina et al,^[@ref9]^ 2000          45      12                     No                          309±63                                    BPRS≥20%                       350                               62% vs 21% P\<0.02                  72%/70%                       BID or TID
  Llorca et al,^[@ref10]^ 2002        37      18                     No                          486                                       PANSS≥20%                      550                               NS                                  64%/51%                       QD or BID (at 6PM and 8 PM)

Risperidone
-----------

Risperidone was released commercially in the USA in 1994. Two major studies, one North American^[@ref11]^ and one European,^[@ref12]^ compared different doses of risperidone. Both favored mid-range daily doses: 6 mg for the North American study, and 4 and 8 mg in the European study. These two studies did not give any indication that higher doses would bring a better response rate. The absence of a dose-response relationship for risperidone has been further confirmed by biological studies. One study^[@ref13]^ could not find any significant, correlation between the plasma concentration of risperidone and clinical response. However, it has been shown that higher doses of risperidone lead to a higher frequency of EPS, and thus they lose the one great advantage that atypicals have brought, ic, the low frequency of EPS.

Olanzapine
----------

Olanzapine has been commercially available in the USA since 1996. As we have seen, clinicians tend to use higher and higher daily doses of olanzapine. However, one would like to have evidence from clinical trials showing that patients, or at least some patients, improve to a greater degree with high doses. Several lines of evidence can be found in the literature. First, in their pivotal randomized clinical trial, Beasley et al1" found that 48% of patients improved with a mean daily dose of 5 mg, while 58% improved with 10 mg and 66% with 15 mg. This leads to the following question: will more patients improve as we continue to increase the dosage of olanzapine? Several case reports have been published describing a better response with an increment of olanzapine dosage above 20 mg/day. A recently published double-blind study^[@ref15]^ has shed more light on this issue. In the first 8 weeks of this study, patients received a fixed daily dose of clozapine (500 mg), olanzapine (20 mg), risperidone (8 mg), or haloperidol (20 mg). In the subsequent 6 weeks, doses were adjusted clinically, although clinicians remained blind to medication. At the end of the study, the average daily dose was 30 mg for olanzapine, 530 mg for clozapine, 12 mg for risperidone, and 26 mg for haloperidol. Interestingly enough, only the patients who were on olanzapine continued to improve as their dose was increased. This tends to show that, doses of olanzapine above the maximal recommended dose may be beneficial for optimizing olanzapine treatment. This finding awaits replication.

One study^[@ref16]^ tried to determine a plasma level threshold for olanzapine using the ROC methodology outlined earlier. In this study, several fixed arms were used, and a cut-off point of 23 ng/mL was shown to be an olanzapine plasma level threshold in order to obtain an optimal response.

Quetiapine
----------

Quetiapine was released commercially in the USA in 1997. Quetiapine has a rather unique receptor profile.

Like clozapine, quetiapine is a low-potency dopamine D~2~ blocker, and one study^[@ref17]^ showed that quetiapine leads to transient high D~2~ occupancy, which decreases to very low levels after 12 h. Two major studies^[@ref18],[@ref19]^ compared various daily doses of quetiapine from 75 mg to 750 mg. It appears that doses above 75 mg are necessary to obtain a response superior to placebo. These studies did not give any indication of a clear dose-response relationship. However, some case reports have indicated that a daily dose above 800 mg brought, a better response for some symptoms. For this reason, some clinical trials comparing usual doses of quetiapine with higher than recommended daily doses (up to 1200 mg) are planned.

Ziprasidone
-----------

Ziprasidone was released commercially in the USA in 2001. Two placebo-controlled studies compared different daily doses of ziprasidone in acute schizophrenia. The first one^[@ref20]^ compared ziprasidone 40 mg/day with ziprasidone 120 mg/day. A daily dose of 40 mg led to a 37% response rate, and a daily dose of 120 mg to a response rate of 49%. In the second study,^[@ref21]^ 29% of the patients improved with a daily dose of 80 mg, versus 31 % of the patients on 160 mg. In each of the two pivotal trials, the higher dose of ziprasidone resulted in a greater efficacy than the lower dose. Dosages greater than 40 mg/day are recommended. This was confirmed in a 1-year, placebo-controlled clinical trial.^[@ref22]^ After 1 year, 43% of patients on 40 mg/day had relapsed versus 35% of the patients on 80 mg/day, and 36% of the patients on 160 mg/day Systematic trials using dosages of 200 mg/day have not yet been reported. It is possible that, higher doses of ziprasidone may lead to higher rates of response.

Aripiprazole
------------

Aripiprazole has been available in the USA since November 2002. For this reason, experience is very limited. The recommended daily dosage is from 10 to 30 mg. From the phase 3 clinical trials, high dosages of 30 mg/day were no more effective than lower dosages of 10 or 15 mg/day. It will be interesting to see whether clinical usage of this compound will confirm this finding. The efficacy of dosages above 30 mg/day is not known.

Conclusions
===========

The determination of an optimal dosage for each atypical neuroleptic is an important issue for the clinical treatment of patients with schizophrenia. For clinicians, it is linked to another important question: when can we consider that a patient has not responded to a specific antipsychotic? In this presentation, it appeared that, (i) for most atypical neuroleptics, little is known; and (ii) for each atypical neuroleptic, a different, answer should apply.

For clozapine, it is recommended to aim for a plasma level above 350 ng/mL for nonresponders and partial responders. It should be specified that, this plasma level should be obtained exactly 12 h after the last dose. For risperidone, optimal dosages range between 4 and 8 mg/day, and there is no indication that a higher dose would bring additional improvement. For olanzapine, a quite different situation is encountered. There is good indication that dosages of 30 and 40 mg/day can increase clinical response. It appears that plasma levels above 23 ng/mL may predict response. For quetiapine, reports on the utility of dosages greater than 800 mg/day are anecdotal at this point, and more studies should be conducted. For ziprasidone, dosages above 40 mg/day should be used, but daily doses above 200 mg have not yet been systematically investigated. For aripiprazole, experience is very limited, but it seems that daily dosages of 10 or 15 mg are as effective as 30 mg.
